These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29695828)

  • 41. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
    Zeuzem S; Ghalib R; Reddy KR; Pockros PJ; Ben Ari Z; Zhao Y; Brown DD; Wan S; DiNubile MJ; Nguyen BY; Robertson MN; Wahl J; Barr E; Butterton JR
    Ann Intern Med; 2015 Jul; 163(1):1-13. PubMed ID: 25909356
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population.
    Kramer JR; Puenpatom A; Cao Y; Yu X; El-Serag HB; Kanwal F
    Am J Drug Alcohol Abuse; 2022 Jul; 48(4):445-453. PubMed ID: 35077656
    [No Abstract]   [Full Text] [Related]  

  • 43. Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
    Elbasha E; Greaves W; Roth D; Nwankwo C
    J Viral Hepat; 2017 Apr; 24(4):268-279. PubMed ID: 27966249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam.
    Nwankwo C; Corman SL; Elbasha EH
    J Infect Public Health; 2019; 12(4):502-508. PubMed ID: 30711348
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3.
    Yeh WW; Fraser IP; Jumes P; Petry A; Lepeleire I; Robberechts M; Reitmann C; Van Dyck K; Huang X; Guo Z; Panebianco D; Nachbar RB; O'Mara E; Wagner JA; Butterton JR; Dutko FJ; Moiseev V; Kobalava Z; Hüser A; Visan S; Schwabe C; Gane E; Popa S; Ghicavii N; Uhle M; Wagner F
    Clin Ther; 2018 May; 40(5):704-718.e6. PubMed ID: 29703432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elbasvir and grazoprevir for the treatment of hepatitis C.
    Wang SJ; Huang CF; Yu ML
    Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1071-1081. PubMed ID: 33428488
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial.
    Boerekamps A; De Weggheleire A; van den Berk GE; Lauw FN; Claassen MAA; Posthouwer D; Bierman WF; Hullegie SJ; Popping S; van de Vijver DACM; Dofferhoff ASM; Kootstra GJ; Leyten EM; den Hollander J; van Kasteren ME; Soetekouw R; Ammerlaan HSM; Schinkel J; Florence E; Arends JE; Rijnders BJA
    Lancet Gastroenterol Hepatol; 2019 Apr; 4(4):269-277. PubMed ID: 30660617
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.
    Lawitz E; Poordad F; Gutierrez JA; Wells JT; Landaverde CE; Evans B; Howe A; Huang HC; Li JJ; Hwang P; Dutko FJ; Robertson M; Wahl J; Barr E; Haber B
    Hepatology; 2017 Feb; 65(2):439-450. PubMed ID: 27770561
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective.
    Alric L; Ollivier-Hourmand I; Bérard E; Hillaire S; Guillaume M; Vallet-Pichard A; Bernard-Chabert B; Loustaud-Ratti V; Bourlière M; de Ledinghen V; Fouchard-Hubert I; Canva V; Minello A; Nguyen-Khac E; Leroy V; Saadoun D; Trias D; Pol S; Kamar N
    Kidney Int; 2018 Jul; 94(1):206-213. PubMed ID: 29735308
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Meta-Analysis of Grazoprevir plus Elbasvir for Treatment of Hepatitis C Virus Genotype 1 Infection.
    Ahmed H; Abushouk AI; Menshawy A; Attia A; Mohamed A; Negida A; Abdel-Daim MM
    Ann Hepatol; 2018; 17(1):18-32. PubMed ID: 29311409
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Elbasvir/Grazoprevir Use in Postliver Transplantation Patients on Hemodialysis.
    Martin MT; Koppe S
    Transplantation; 2017 Sep; 101(9):2088-2091. PubMed ID: 28376038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection.
    Lai PC; Chen CH; Jeng LB; Yu TM; Tsai SF; Wu MJ; Cheng SB; Yang SS; Lee TY
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0200321. PubMed ID: 34902265
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of elbasvir/grazoprevir in treatment-naive Chinese adults with hepatitis C virus infection: A randomized trial.
    Wei L; Jia JD; Duan ZP; Wang FS; Niu JQ; Xie W; Huang WX; Zhang MX; Huang Y; Wang MR; Wu SM; Zhao YR; Jia ZS; Zhao XM; Mu SM; Liang LW; Wang Z; Puenpatom A; Hwang P; Robertson MN; Ingravallo P; Asante-Appiah E; Wei B; Evans B; Hanna GJ; Talwani R
    JGH Open; 2020 Dec; 4(6):1065-1073. PubMed ID: 33319038
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial.
    Lagging M; Brown A; Mantry PS; Ramji A; Weilert F; Vierling JM; Howe A; Gendrano IN; Hwang P; Zhang B; Wahl J; Robertson M; Mobashery N
    J Viral Hepat; 2016 Feb; 23(2):80-8. PubMed ID: 26353843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.
    Caro L; Wenning L; Feng HP; Guo Z; Du L; Bhagunde P; Fandozzi C; Panebianco D; Marshall WL; Butterton JR; Iwamoto M; Yeh WW
    Eur J Clin Pharmacol; 2019 May; 75(5):665-675. PubMed ID: 30680407
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
    Toyoda H; Atsukawa M; Takaguchi K; Senoh T; Michitaka K; Hiraoka A; Fujioka S; Kondo C; Okubo T; Uojima H; Tada T; Yoneyama H; Watanabe T; Asano T; Ishikawa T; Tamai H; Abe H; Kato K; Tsuji K; Ogawa C; Shimada N; Iio E; Deguchi A; Itobayashi E; Mikami S; Moriya A; Okubo H; Tani J; Tsubota A; Tanaka Y; Masaki T; Iwakiri K; Kumada T
    J Gastroenterol; 2018 Dec; 53(12):1276-1284. PubMed ID: 29740665
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.
    Zarębska-Michaluk D; Jaroszewicz J; Buczyńska I; Simon K; Lorenc B; Tudrujek-Zdunek M; Tomasiewicz K; Sitko M; Garlicki A; Janczewska E; Dybowska D; Halota W; Pawłowska M; Pabjan P; Mazur W; Czauż-Andrzejuk A; Berak H; Horban A; Socha Ł; Klapaczyński J; Piekarska A; Blaszkowska M; Belica-Wdowik T; Dobracka B; Tronina O; Deroń Z; Białkowska-Warzecha J; Laurans Ł; Flisiak R
    J Gastroenterol Hepatol; 2020 Jul; 35(7):1238-1246. PubMed ID: 31734959
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.
    Hézode C; Colombo M; Bourlière M; Spengler U; Ben-Ari Z; Strasser SI; Lee WM; Morgan L; Qiu J; Hwang P; Robertson M; Nguyen BY; Barr E; Wahl J; Haber B; Chase R; Talwani R; Marco VD;
    Hepatology; 2017 Sep; 66(3):736-745. PubMed ID: 28256747
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
    Rockstroh JK; Nelson M; Katlama C; Lalezari J; Mallolas J; Bloch M; Matthews GV; Saag MS; Zamor PJ; Orkin C; Gress J; Klopfer S; Shaughnessy M; Wahl J; Nguyen BY; Barr E; Platt HL; Robertson MN; Sulkowski M
    Lancet HIV; 2015 Aug; 2(8):e319-27. PubMed ID: 26423374
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
    Dore GJ; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Grebely J; Howe AY; Gendrano IN; Chen E; Huang HC; Dutko FJ; Nickle DC; Nguyen BY; Wahl J; Barr E; Robertson MN; Platt HL;
    Ann Intern Med; 2016 Nov; 165(9):625-634. PubMed ID: 27537841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.